A phase I/II study of trichosanthin treatment of HIV disease
| Autor: | Michael R. Price, Barbara Starrett, Robert Mayer, Larry Waites, Vera S. Byers, Martin Delaney, Robert W. Baldwin, Alan S. Levin, Richard A Robins, J. A. Clegg |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Coma
Drug medicine.medical_specialty business.industry Microgram media_common.quotation_subject Immunology Trichosanthin medicine.disease Gastroenterology Infectious Diseases Phase i ii Maximum tolerated dose Internal medicine medicine Immunology and Allergy Dementia medicine.symptom business Hiv disease media_common |
| Zdroj: | Aids. 4:1189-1196 |
| ISSN: | 0269-9370 |
| Popis: | Trichosanthin, a ribosomal inhibitor protein, blocks HIV replication in lymphocytes and macrophages. This agent was used to treat 51 patients with advanced HIV disease in a dose-escalation study in which three injections were administered over a 9-21-day period in a dose range of 10-30 micrograms/kg per injection. The maximum tolerated dose was estimated to be 30 micrograms/kg. Reversible but severe fatigue and myalgias were the major dose-limiting side-effects; mild leucocytosis and elevations in serum transaminases were noted and were reversible. Non-dose-related reversible mental status changes were seen in six patients and were considered to be associated with the drug. This was usually manifest as dementia, but progressed to coma in two patients. This reversed, but the sequelae resulted in death in one patient. Decreases in serum p24 antigen levels were noted 1 month after the first infusion in 10 of 18 patients who entered the study with elevated levels; one converted to negative. Values usually remained low to the end of the study period (2 months). In those patients with CD4+ cell levels greater than 50 x 10(6) cells/l significant decreases in sedimentation rate and increases in CD4+ cell numbers were also noted. These changes were found at all dose levels but only in patients receiving three infusions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|